2026 Global: Bladder Cancer Molecular Diagnostics Market -Competitive Review (2032) report
Description
The 2026 Global: Bladder Cancer Molecular Diagnostics Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for bladder cancer molecular diagnostics market by geography and historical trend. The scope of the report extends to sizing of the bladder cancer molecular diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Roche, Abbott, Thermo Fisher Scientific, Illumina, Qiagen, Danaher (Beckman Coulter and Cepheid), Exact Sciences, Guardant Health, Myriad Genetics, and Bio‑Rad are widely recognized as the ten major companies shaping the bladder cancer molecular diagnostics market. Roche leverages its broad diagnostics portfolio, including tissue- and liquid‑biopsy platforms and companion diagnostics, to provide integrated molecular workflows for bladder cancer detection, stratification, and treatment selection, supported by strong global lab distribution and regulatory experience. Abbott contributes established cytogenetic and molecular tests such as UroVysion and continues to expand urine‑based assays and automated platforms that enable high‑throughput screening and recurrence monitoring in clinical practice. Thermo Fisher Scientific supplies NGS instruments, targeted panels, and sample‑prep chemistries that underpin many bladder cancer genomic assays and array‑based profiling solutions used in translational and clinical laboratories worldwide. Illumina dominates high‑throughput sequencing and array markets with oncology panels and bioinformatics ecosystems that drive discovery and clinical implementation of bladder cancer biomarkers, particularly in multi‑gene and methylation profiling applications. Qiagen offers PCR‑based assays, liquid biopsy solutions, and sample‑to‑result platforms tailored to urinary and tissue specimens, positioning the firm as a key provider for sensitive mutation detection and companion diagnostic needs in bladder oncology.
Danaher, through its diagnostics subsidiaries including Beckman Coulter and Cepheid, supplies automated molecular platforms, cartridge‑based PCR tests, and laboratory automation systems that facilitate rapid, near‑patient bladder cancer testing and routine surveillance workflows. Exact Sciences, with expertise in noninvasive cancer screening and commercially scaled molecular assays, is advancing urine‑based biomarker panels and molecular recurrence monitoring products that target earlier detection and longitudinal surveillance of bladder cancer. Guardant Health focuses on circulating tumor DNA (ctDNA) assays and liquid biopsy solutions that enable minimally invasive detection of actionable alterations, treatment response monitoring, and residual disease assessment in bladder cancer care pathways. Myriad Genetics brings experience in hereditary cancer panels, tumor profiling, and predictive biomarker assays that support risk stratification, therapeutic selection, and prognostic modeling for bladder cancer patients. Bio‑Rad develops molecular reagents, ddPCR and qPCR platforms, and assay kits used in research and clinical labs for sensitive mutation and copy‑number analyses relevant to bladder cancer biomarker validation and routine testing.
Collectively these companies supply complementary technologies—NGS and array platforms, PCR and cartridge systems, ddPCR, ctDNA assays, and integrated bioinformatics—that enable discovery, clinical validation, and commercialization of urine‑ and tissue‑based molecular diagnostics for bladder cancer, while ongoing partnerships, regulatory clearances, and product launches continue to expand test sensitivity, specificity, and accessibility across hospitals and reference laboratories globally.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for bladder cancer molecular diagnostics market by geography and historical trend. The scope of the report extends to sizing of the bladder cancer molecular diagnostics market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Roche, Abbott, Thermo Fisher Scientific, Illumina, Qiagen, Danaher (Beckman Coulter and Cepheid), Exact Sciences, Guardant Health, Myriad Genetics, and Bio‑Rad are widely recognized as the ten major companies shaping the bladder cancer molecular diagnostics market. Roche leverages its broad diagnostics portfolio, including tissue- and liquid‑biopsy platforms and companion diagnostics, to provide integrated molecular workflows for bladder cancer detection, stratification, and treatment selection, supported by strong global lab distribution and regulatory experience. Abbott contributes established cytogenetic and molecular tests such as UroVysion and continues to expand urine‑based assays and automated platforms that enable high‑throughput screening and recurrence monitoring in clinical practice. Thermo Fisher Scientific supplies NGS instruments, targeted panels, and sample‑prep chemistries that underpin many bladder cancer genomic assays and array‑based profiling solutions used in translational and clinical laboratories worldwide. Illumina dominates high‑throughput sequencing and array markets with oncology panels and bioinformatics ecosystems that drive discovery and clinical implementation of bladder cancer biomarkers, particularly in multi‑gene and methylation profiling applications. Qiagen offers PCR‑based assays, liquid biopsy solutions, and sample‑to‑result platforms tailored to urinary and tissue specimens, positioning the firm as a key provider for sensitive mutation detection and companion diagnostic needs in bladder oncology.
Danaher, through its diagnostics subsidiaries including Beckman Coulter and Cepheid, supplies automated molecular platforms, cartridge‑based PCR tests, and laboratory automation systems that facilitate rapid, near‑patient bladder cancer testing and routine surveillance workflows. Exact Sciences, with expertise in noninvasive cancer screening and commercially scaled molecular assays, is advancing urine‑based biomarker panels and molecular recurrence monitoring products that target earlier detection and longitudinal surveillance of bladder cancer. Guardant Health focuses on circulating tumor DNA (ctDNA) assays and liquid biopsy solutions that enable minimally invasive detection of actionable alterations, treatment response monitoring, and residual disease assessment in bladder cancer care pathways. Myriad Genetics brings experience in hereditary cancer panels, tumor profiling, and predictive biomarker assays that support risk stratification, therapeutic selection, and prognostic modeling for bladder cancer patients. Bio‑Rad develops molecular reagents, ddPCR and qPCR platforms, and assay kits used in research and clinical labs for sensitive mutation and copy‑number analyses relevant to bladder cancer biomarker validation and routine testing.
Collectively these companies supply complementary technologies—NGS and array platforms, PCR and cartridge systems, ddPCR, ctDNA assays, and integrated bioinformatics—that enable discovery, clinical validation, and commercialization of urine‑ and tissue‑based molecular diagnostics for bladder cancer, while ongoing partnerships, regulatory clearances, and product launches continue to expand test sensitivity, specificity, and accessibility across hospitals and reference laboratories globally.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.